A Multicenter, Randomized, Double Blind, Vehicle-Controlled Study to Evaluate the Safety and Effect on Sweat Production of 3 Concentrations of Topically Applied BBI-4000 in Subjects With Axillary Hyperhidrosis

Trial Profile

A Multicenter, Randomized, Double Blind, Vehicle-Controlled Study to Evaluate the Safety and Effect on Sweat Production of 3 Concentrations of Topically Applied BBI-4000 in Subjects With Axillary Hyperhidrosis

Completed
Phase of Trial: Phase II

Latest Information Update: 07 Mar 2016

At a glance

  • Drugs Sofpironium bromide (Primary)
  • Indications Hyperhidrosis
  • Focus Therapeutic Use
  • Sponsors Brickell Biotech
  • Most Recent Events

    • 07 Mar 2016 Results published at the at the 74th American Academy of Dermatology Annual Meeting, as per Brickell Biotech media release.
    • 07 Mar 2016 Results published in Brickell Biotech media release.
    • 17 Dec 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top